Pfizer Inc. (NYSE: PFE) Study Shows The Company Gives Equitable Pay to Workers

Pfizer Inc. (NYSE: PFE) has stated for the third time that a compensation expert has recognized that the company offers equitable pay to workers.

This announcement came after a study on gender-based pay worldwide and for U.S minorities. It used bonuses, merit increases, and base pay to assess payment equity. The study also adjusted for location, experience, job level, grade, and role.

The results showed that Pfizer’s compensation for female employees was more than 99.4% of what their colleagues across the globe received. This figure was an increase from 99.3% in 2020. Moreover, its minority employees received a dollar for dollar parity (100%) compared to 99.8% in 2020.

Pfizer previously launched the 2025 Opportunity Parity initiative to increase female and minority representation at senior-level positions. The company has released its results from 2020 and will continue to do so.

Pfizer announces webcast on March

Meanwhile, the company invites investors to a webcast where the Executive Vice President, Chief Digital and Technology Officer from the Truist Securities Life Sciences AI Symposium- Biotech and Tools, Lidia Fonseca, will speak. This webcast will take place on March 1, 2022, at 12.30 pm Eastern Standard Time.

Paxlovid is more available as omicron infection subsides

When omicron infections in the U.S when at an all-time high, it was complicated for pharmacies and hospitals to get their hands in Paxlovid. This drug, which Pfizer developed, was the first line of treatment for COVID-19 infection. The breakthrough oral pill was a game-changer as it would be easier to administer to patients with infections.

The drug has received approval from the Food and Drug Administration (FDA) and the Center for Disease Control and Prevention (CDC). The pill is to be taken for five days to treat COVID-19. Despite its approval, the company could not keep up with the demand due to coronavirus spikes.

Fortunately, as the omicron cases subside, the drug has become readily available to schools and healthcare facilities in the U.S. On a website which the federal government runs, 130,000 courses of Paxlovid are available. Moreover, the website indicates the healthcare providers and pharmacies with the drug.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither WallStreetPR.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at WallStreetPR.com/Disclaimer.

Published by Steve Hackney

Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.